Ceftriaxone/disodium-edetate/sulbactam - Venus Remedies

Drug Profile

Ceftriaxone/disodium-edetate/sulbactam - Venus Remedies

Alternative Names: Ceftriaxone/EDTA/sulbactam - Venus Remedies; Ceftriaxone/sulbactam/edetic acid fixed dose combination – Venus Remedies; CSE-1034; ELORES; Sulbactomax

Latest Information Update: 04 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Venus Remedies
  • Class Adjuvants; Antibacterials; Cephalosporins; Ethylenediamines; Penicillins; Small molecules
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Nosocomial infections

Most Recent Events

  • 15 Feb 2016 Preregistration for Nosocomial infections is ongoing in European Union (IV)
  • 15 Feb 2016 No development reported - Preregistration for Nosocomial infections in Japan (IV)
  • 15 Feb 2016 No development reported - Preregistration for Nosocomial infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top